The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
A biparatopic anti‐EGFR nanobody efficiently inhibits solid tumour growth
Open accessAbstract
The epidermal growth factor receptor (EGFR) has been shown to be a valid cancer target for antibody‐based therapy. At present, several anti‐EGFR monoclonal antibodies have been successfully used, such as cetuximab and matuzumab. X‐ray crystallography data show that these antibodies bind to different epitopes on the ecto‐domain of EGFR, providing a rationale for the combined use of these two antibody specificities. We have previously reported on the successful isolation of antagonistic anti‐EGFR nanobodies. In our study, we aimed to improve the efficacy of these molecules by combining nanobodies with specificities similar to both cetuximab and matuzumab into a single biparatopic molecule. Carefully designed phage nanobody selections resulted in two sets of nanobodies that specifically blocked the binding of either matuzumab or cetuximab to EGFR and that did not compete for each others' binding. A combination of nanobodies from both epitope groups into the biparatopic nanobody CONAN‐1 was shown to block EGFR activation more efficiently than monovalent or bivalent (monospecific) nanobodies. In addition, this biparatopic nanobody potently inhibited EGF‐dependent cell proliferation. Importantly, in an in vivo model of athymic mice bearing A431 xenografts, CONAN‐1 inhibited tumour outgrowth with an almost similar potency as the whole mAb cetuximab, despite the fact that CONAN‐1 is devoid of an Fc portion that could mediate immune effector functions. Compared to therapy using bivalent, monospecific nanobodies, CONAN‐1 was clearly more potent in tumour growth inhibition. These results show that the rational design of biparatopic nanobody‐based anticancer therapeutics may yield potent lead molecules for further development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Giard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,289
Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., & Winter, G. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90498-u · Cited by 1,603
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Epidermal growth factor receptor: Mechanisms of activation and signalling
Jorissen, R. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00098-8 · Cited by 1,565
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
Li, S., Schmitz, K. R., Jeffrey, P. D., Wiltzius, J. J. W., Kussie, P., & Ferguson, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.003 · Cited by 1,118
Self-citationBuday, L., & Downward, J. (1993) · Cell · doi:10.1016/0092-8674(93)90146-h · Cited by 1,079
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Zhu, H.-J., Walker, F., Frenkel, M. J., Hoyne, P. A., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00940-6 · Cited by 783
Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides
Stemmer, W. P. C., Crameri, A., Ha, K. D., Brennan, T. M., & Heyneker, H. L. (1995) · Gene · doi:10.1016/0378-1119(95)00511-4 · Cited by 728
Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras
Gale, N. W., Kaplan, S., Lowenstein, E. J., Schlessinger, J., & Bar-Sagi, D. (1993) · Nature · doi:10.1038/363088a0 · Cited by 563
Selection of phage antibodies by binding affinity
Hawkins, R. E., Russell, S. J., & Winter, G. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90639-2 · Cited by 520
Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins
Dennis, M. S., Zhang, M., Meng, Y. G., Kadkhodayan, M., Kirchhofer, D., Combs, D., & Damico, L. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205854200 · Cited by 508
HONEGGER, A. (1987) · Cell · doi:10.1016/0092-8674(87)90147-4 · Cited by 475
Merlino, G. T., Xu, Y.-H., Ishii, S., Clark, A. J. L., Semba, K., Toyoshima, K., Yamamoto, T., & Pastan, I. (1984) · Science · doi:10.1126/science.6200934 · Cited by 401
Structure-Based View of Epidermal Growth Factor Receptor Regulation
Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368
Self-citationPrigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies
Roovers, R. C., Laeremans, T., Huang, L., De Taeye, S., Verkleij, A. J., Revets, H., de Haard, H. J., & van Bergen en Henegouwen, P. M. P. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0180-4 · Cited by 346
Self-citationTijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Self-citationCoppieters, K., Dreier, T., Silence, K., Haard, H. D., Lauwereys, M., Casteels, P., Beirnaert, E., Jonckheere, H., Wiele, C. V. D., Staelens, L., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21827 · Cited by 303
Els Conrath, K., Lauwereys, M., Wyns, L., & Muyldermans, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007734200 · Cited by 300
Efficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Hassanzadeh Gh., G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260
Clayton, A. H. A., Walker, F., Orchard, S. G., Henderson, C., Fuchs, D., Rothacker, J., Nice, E. C., & Burgess, A. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504770200 · Cited by 256
Gainkam, L. O. T., Huang, L., Caveliers, V., Keyaerts, M., Hernot, S., Vaneycken, I., Vanhove, C., Revets, H., De Baetselier, P., & Lahoutte, T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.048538 · Cited by 222
ErbB3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor
Soltoff, T. P., Carraway, K. L., Prigent, S. A., Gullick, W. G., & Cantley, L. C. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.6.3550-3558.1994 · Cited by 205
RTK mutations and human syndromes: when good receptors turn bad
Robertson, S. C., Tynan, J., & Donoghue, D. J. (2000) · Trends in Genetics · doi:10.1016/s0168-9525(00)02077-1 · Cited by 168
Matuzumab Binding to EGFR Prevents the Conformational Rearrangement Required for Dimerization
Schmiedel, J., Blaukat, A., Li, S., Knöchel, T., & Ferguson, K. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.02.019 · Cited by 154
Self-citationExtracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors
Ferguson, K. M., Darling, P. J., Mohan, M. J., Macatee, T. L., & Lemmon, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4632 · Cited by 154
Self-citationTargeting of adenoviral vectors through a bispecific single-chain antibody
Haisma, H. J., Grill, J., Curiel, D. T., Hoogeland, S., van Beusechem, V. W., Pinedo, H. M., & Gerritsen, W. R. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700198 · Cited by 147
Johns, T. G., Adams, T. E., Cochran, J. R., Hall, N. E., Hoyne, P. A., Olsen, M. J., Kim, Y., Rothacker, J., Nice, E. C., Walker, F., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401218200 · Cited by 144
Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
Li, S., Kussie, P. H., & Ferguson, K. M. (2008) · Structure · doi:10.1016/j.str.2007.11.009 · Cited by 122
Self-citationLigand-induced EGF Receptor Oligomerization Is Kinase-dependent and Enhances Internalization
Hofman, E. G., Bader, A. N., Voortman, J., van den Heuvel, D. J., Sigismund, S., Verkleij, A. J., Gerritsen, H. C., & Henegouwen, P. M. P. V. B. E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164731 · Cited by 104
Self-citationThe status and role of ErbB receptors in human cancer
Überall, I., Kolář, Z., Trojanec, R., Berkovcová, J., & Hajdúch, M. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.12.002 · Cited by 92
Interaction of antibodies with ErbB receptor extracellular regions
Schmitz, K. R., & Ferguson, K. M. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.10.008 · Cited by 91
Self-citationde Haard, H., Bezemer, S., Ledeboer, A. M., Müller, W. H., Boender, P. J., Moineau, S., Coppelmans, M.-C., Verkleij, A. J., Frenken, L. G. J., & Verrips, C. T. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.13.4531-4541.2005 · Cited by 77
Self-citationNanobodies in therapeutic applications.
Roovers, R. C., van Dongen, G. A. M. S., & Henegouwen, P. M. P. V. B. E. (2007) · PubMed · Cited by 72
Self-citationRoovers, R. C., Henderikx, P., Helfrich, W., van der Linden, E. P. M., Reurs, A. W., de Bruı̈ne, A. P., Arends, J. W., de Leij, L., & Hoogenboom, H. R. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.700 · Cited by 57
Self-citationEnhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425
Kamat, V., Donaldson, J. M., Kari, C., Quadros, M. R. D., Lelkes, P. I., CHAIKEN, I. M., Cocklin, S., Williams, J. C., Papazoglou, E. S., & Rodeck, U. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.6097 · Cited by 56
Patel, D. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.11-supp.31s · Cited by 35
Methods for Labeling Thyroxine With Radioactive Iodine
Frieden, E., Lipsett, M. B., & Winzler, R. J. (1948) · Science · doi:10.1126/science.107.2779.353 · Cited by 20
Cited by
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
“CONAN-1 was also more potent than bivalent, monospecific nanobodies in inhibiting tumor growth (64).”
BackgroundInfluentialA robust pipeline for rapid production of versatile nanobody repertoires
Fridy, P. C., Li, Y., Keegan, S., Thompson, M. K., Nudelman, I., Scheid, J. F., Oeffinger, M., Nussenzweig, M. C., Fenyö, D., Chait, B. T., et al. (2014) · Nature Methods · doi:10.1038/nmeth.3170 · Cited by 499
Nanobodies as therapeutics: big opportunities for small antibodies
Steeland, S., Vandenbroucke, R. E., & Libert, C. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.003 · Cited by 468
Muyldermans, S. (2021) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-021419-083831 · Cited by 338
Metadata
- Authors
- Roovers, R. C., Vosjan, M. J. W. D., Laeremans, T., el Khoulati, R., de Bruin, R. C. G., Ferguson, K. M., Verkleij, A. J., van Dongen, G. A. M. S., & van Bergen en Henegouwen, P. M. P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-08-08
- Volume
- 129
- Issue
- 8
- Pages
- 2013-2024
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2088080828
- Cited by
- 284
- References
- 41
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.